Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 February 2004, Vol. 103, No. 4, pp. 1229-1236.
Prepublished online as a Blood First Edition Paper on October 9, 2003; DOI 10.1182/blood-2003-06-2167.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-06-2167v1
103/4/1229    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuwana, M.
Right arrow Articles by Ikeda, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuwana, M.
Right arrow Articles by Ikeda, Y.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Immunobiology
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura

Masataka Kuwana, Shosaku Nomura, Kingo Fujimura, Toshiro Nagasawa, Yoshitomo Muto, Yoshiyuki Kurata, Shigeru Tanaka, and Yasuo Ikeda

From the Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan; the Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; the First Department of Internal Medicine, Kansai Medical University, Osaka, Japan; the Department of Hematology and Oncology, Division of Pharmacotherapeutics, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; the Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan; the Department of Hematology, Toranomon Hospital, Tokyo, Japan; the Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan; and Eisai Company Ltd, Tokyo, Japan.

Blockade of the CD40/CD154 signal is a potential immunomodulatory strategy for T-cell–mediated diseases. As a part of a phase 1, multicenter, dose-escalating trial of humanized monoclonal antibody to CD154 (IDEC-131/E6040) in patients with refractory immune thrombocytopenic purpura (ITP), the autoimmune response to glycoprotein IIb/IIIa (GPIIb/IIIa) was evaluated at successive time points. Five patients each were given a single infusion of 1, 2, 5, or 10 mg/kg IDEC-131/E6040 and followed for 3 months. All adverse events were mild, and there were no severe infections or thromboembolic events. No increase in platelet count was observed in patients treated at 1, 2, or 5 mg/kg, but an increase was observed in 3 patients treated at 10 mg/kg. In only the patients treated at 5 or 10 mg/kg, the frequency of B cells producing anti-GPIIb/IIIa antibodies, GPIIb/IIIa-induced T-cell proliferation, and anti-GPIIb/IIIa antibody production by antigen-dependent T–B-cell collaboration were all suppressed in parallel after the treatment, with a slow return to baseline. In contrast, T-cell response to an irrelevant antigen was not affected. These findings suggest that CD40/CD154 blockade therapy is potentially effective for refractory ITP, through selective suppression of autoreactive T and B cells to platelet antigens.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Anti-CD40L: biology and therapy in ITP
Joseph Schwartz and James B. Bussel
Blood 2004 103: 1178-1179. [Full Text] [PDF]



This article has been cited by other articles:


Home page
GutHome page
S Danese, F Scaldaferri, S Vetrano, T Stefanelli, C Graziani, A Repici, R Ricci, G Straface, A Sgambato, A Malesci, et al.
Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease
Gut, September 1, 2007; 56(9): 1248 - 1256.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Sukati, H. G. Watson, S. J. Urbaniak, and R. N. Barker
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura
Blood, May 15, 2007; 109(10): 4528 - 4538.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Nakamura, Y. Tanaka, T. Satoh, M. Kawai, M. Hirakata, J. Kaburaki, Y. Kawakami, Y. Ikeda, and M. Kuwana
Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism
Rheumatology, February 1, 2006; 45(2): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pediatric Oncology NursingHome page
N. Sevier and M. Houston
Chronic Refractory ITP in Children: Beyond Splenectomy
Journal of Pediatric Oncology Nursing, May 1, 2005; 22(3): 145 - 151.
[Abstract] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020